Merus (MRUS) Price Target Raised at BMO After Positive Phase 2 Data
BMO Capital Markets maintained its Outperform rating on Merus N.V. (NASDAQ:MRUS) shares on May 24 while raising its price target from $96 to $110.
The revision comes after encouraging Phase 2 data for Merus' drug candidates petosemtamab and pembrolizumab (pembro) were released. The drugs are intended to treat recurrent or metastatic Head and neck squamous cell carcinoma (HNSCC).
Presented at the American Society of Clinical Oncology (ASCO), Merus' updated data included findings from an analysis of 43 evaluable patients conducted on February 27, 2025. With a confirmed Objective Response Rate (ORR) of 63%, the study demonstrated robust and long-lasting responses. Notably, a 79% survival rate was shown by the 12-month Overall Survival data. The standard of care for pembrolizumab, which carries a reported survival rate of roughly 50–59%, compares favorably to this.
The market's response to the ASCO presentation indicates that petosemtamab's clinical potential to take the HNSCC treatment landscape to new heights is well-supported. The price target increase and revised estimates also demonstrate growing investor confidence in the drug's prospects. Evan David Seigerman of BMO Capital backed this assessment after the approval probability rose from 85% to 90%, pointing to favorable safety data.
While we acknowledge the potential of MRUS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRUS and that has 100x upside potential, check out our report about the cheapest AI stock.
Read More: and .
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
16 minutes ago
- Washington Post
GOP tax bill would ease regulations on gun silencers and some rifles and shotguns
WASHINGTON — The massive tax and spending cuts package that President Donald Trump wants on his desk by July 4 would loosen regulations on gun silencers and certain types of rifles and shotguns, advancing a longtime priority of the gun industry as Republican leaders in the House and Senate try to win enough votes to pass the bill.
Yahoo
20 minutes ago
- Yahoo
Lake Street: AMT-130 Could Be Game-Changer For ClearPoint
uniQure N.V. (NASDAQ:QURE) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Lake Street Capital reiterated its Buy rating and $30 price target for ClearPoint following uniQure N.V. (NASDAQ:QURE) regulatory update on AMT-130, an experimental gene therapy for Huntington's disease. A team of scientists in lab coats studying a microscope, working on developing gene therapy solutions. uniQure N.V. (NASDAQ:QURE) declared that it has partnered with the FDA to seek an expedited approval process for AMT-130. If the trials go well and the FDA approves it, Lake Street sees AMT-130 as maybe ClearPoint's first 'meaningful partner asset.' ClearPoint provides disposables valued at almost $20,000 for each AMT-130 infusion, suggesting a significant financial benefit associated with the therapy's effectiveness. The FDA's support might result in the approval by the end of 2026, which would have a big effect on ClearPoint's financial standing and confirm its strategic focus on image-guided neurosurgery and gene therapy delivery. According to Lake Street, this regulatory milestone increases clarity on ClearPoint's contribution to the advancement of clinical-stage gene treatments and provides further assurance regarding the clearance timeline for AMT-130. While we acknowledge the potential of QURE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Barclays Initiates BioMarin Pharmaceutical Inc. (BMRN) with a Buy Rating
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Gena Wang of Barclays kept BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) at a Buy rating with a price target of $86.00 in a report published on June 10. A pharmaceutical plant manufacturing a proprietary synthetic oral form of a C-type natriuretic peptide. According to BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)'s most recent earnings report, the firm made $745.15 million in revenue and $185.69 million in net profit for the quarter that ended on March 31. The company's sales were $648.83 million, and its net profit was $88.66 million last year. It is challenging to avoid past comparisons with Genzyme (bought by Sanofi) as BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) builds a portfolio of genetic-disease therapies. Despite having several authorized treatments, the firm spent years in the red due to commercialization and R&D costs, but analysts are optimistic about the long-term, profitable potential of its present portfolio. It is in a strong position because of its extensive internal pipeline and capacity to add expansion through strategic acquisitions. While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.
